Placebo - IV
Sponsors
Eli Lilly and Company
Conditions
Alzheimer DiseaseDyslipidemiasHealthyPsoriasis
Phase 1
A Multiple Dose Study of LY2541546 in Healthy Postmenopausal Women
CompletedNCT01742091
Start: 2009-09-30End: 2010-03-31Updated: 2018-07-18
A Safety Study of Mirikizumab (LY3074828)
CompletedNCT01947933
Start: 2013-10-31End: 2015-02-28Updated: 2024-07-25
A Study of Mirikizumab (LY3074828) in Healthy Participants
CompletedNCT02568423
Start: 2015-12-02End: 2018-10-24Updated: 2024-02-08
A Study of LY3303560 in Participants With Mild Cognitive Impairment or Alzheimer's Disease
CompletedNCT03019536
Start: 2017-01-31End: 2019-06-05Updated: 2023-10-10
A Study of LY3316531 in Healthy Participants and in Participants With Psoriasis
CompletedNCT03418493
Start: 2018-01-30End: 2019-07-29Updated: 2023-09-21
A Study of LY3361237 in Healthy Participants
CompletedNCT03695198
Start: 2018-10-26End: 2019-08-29Updated: 2019-09-04
A Study of LY3475766 in Healthy Participants
CompletedNCT04052594
Start: 2019-09-03End: 2021-03-31Updated: 2021-04-28
A Study of Mirikizumab in Healthy Chinese Participants
CompletedNCT04137380
Start: 2019-12-04End: 2020-12-11Updated: 2024-01-26
A Safety Study of LY3462817 and LY3509754 in Participants With Psoriasis
TerminatedNCT04152382
Start: 2019-11-20End: 2022-02-09Updated: 2022-03-15
A Study of LY3478006 in Healthy Participants
TerminatedNCT04230122
Start: 2020-02-17End: 2020-06-04Updated: 2021-12-06
A Study of Ramucirumab (LY3009806) in Healthy Participants
CompletedNCT04495478
Start: 2020-07-30End: 2021-05-09Updated: 2023-02-14